Azịza ngwa ngwa
Two antigen peptide pools can carry the same catalogue label and still not be interchangeable, so the question a lab should ask before ordering is not whether …
Gịnị na-eme 2035 amụma ọdọ mmiri antigen peptide kwuru n'ezie, na gịnị ka ọ pụtara maka ka ụlọ nyocha si azụta ọdọ mmiri?
Ụlọ ọrụ mmepụta ihe Peptide Ngwakọta Peptide Atụmatụ ahịa ahụ e zoro aka na ya bụ ụdị azụmaahịa nwere echiche gbasara oke na uto. Ọ naghị egosi na ọtụtụ ndị na-eweta ngwaahịa ga-abawanye ohere ịzụ ahịa. Tọdo nkọwapụta na nyocha n'ezie na ihe egwu ihe.
Ọkwa amụma ahụ kewara ihe maka nkọwapụta karịa maapụ mpaghara. Ihe-ọkwa nyocha na-achịkwa olu ebe GMP-ọkwa na-ewe oke uru na ọnụahịa adịchaghị, stringent iru eru na ndị ahịa mkpọchi-na (IndexBox, 2026-10-11). Ọ nweghị pasenti na-eso ndị kewara, ya mere onye na-azụ ihe enweghị ike ịgụ oke iru eru na ya.
Amụma ahụ na-akpọkwa ihe mgbochi nke ya: GMP n'ichepụta mgbagwoju anya, ogologo oge ndu, ntozu na nkwado ego, ike-nyocha regulatory ejighị n'aka, na oke nnyenye-nnọọ (IndexBox, 2026-10-11). Nke ọ bụla n'ime ha bụ ibu akwụkwọ na-adaba na nkọwapụta nke onye zụrụ ya, ọ bụ ya mere ihe ndị ọzọ n’isiokwu a bụ maka ihe a ga-ede karịa katalọgụ a ga-emepe.
Kedu ihe bụ ọdọ mmiri peptide antigen, na gịnị kpatara Melan-A/MART-1 bụ ọkọlọtọ na-arụ ọrụ atụ?
Ọdọ mmiri antigen peptide bụ nkọwapụta nke peptides sịntetik na-ekpuchi ihe na-agbasa protein e lekwasịrị anya., ewepụtara ya ọnụ ka otu mkpali kpuchiri ọtụtụ epitopes ndị ndoro-ndoro anya. The mmadụ Melan-A/MART-1 ọdọ mmiri e wuru dị ka 27 peptides 15-mer na-ejikọta ya na 11-amino-acid ndakọta, na-enyocha protein zuru oke nke 118-amino-acid edere n'okpuru ntinye UniProt nyochara Q16655 (peptides.de, ibe akwụkwọ katalọgụ emechiela ya).
Mgbakọ nke 15-mer/11-aa abụghị ihe nchoputa nọọrọ onwe ya anọ. Ọ na-apụta na ibe ọdọ mmiri nke ndị na-eweta ya, na akwụkwọ ntuziaka onye ọrụ PepMix JPT, na ibe ọdọ mmiri ndị ọzọ na-ere ahịa, na n'ime usoro ndị ọgbọ nyochara ngalaba, ma elu bụ ọkọlọtọ imewe onye na-ere ahịa n'onwe ya, nakweere gafee ubi. Were ya dị ka otu isi mmalite gbakwunyere nkwupụta mmeghari nke onwe, ọ bụghị dị ka convergent ihe àmà.
Melan-A/MART-1 na-enweta ọnọdụ ya dị ka ihe atụ na-arụ ọrụ na usoro ọmụmụ na ojiji. Kawakami na ndị ọrụ ibe' 1994 Akuko PNAS mere ka a mata mkpụrụ ndụ ihe nketa site na cDNA okwu cloning nke melanoma antigen nke mmadụ na-eketa nke HLA-A2 na-egbochi tumor-infiltrating lymphocytes ghọtara., na-edobe protein na-egbochi melanoma na ahịrị sel melanocyte na retina mmadụ (PubMed, Eprel 1994). Otu ihe 1994 Akwukwo na-akọwa protin nke melanocyte ahịrị-kpọmkwem protein MART-1 dị ka antigen melanoma na-ekesa nke ọma site na T lymphocytes nke ndị ọrịa nwere ajọ ọrịa siri ike..
Sørensen na ndị ọrụ ibe nyochaa nke MART-1 epitope na-ekwu na n'ime ndị a ma ama na-emetụta tumor antigens ghọtara site na mmadụ CD8 T cell., Melan-A/MART-1 bụ otu n'ime ndị kacha, ọ bụrụ na ọ bụghị kacha, ebumnuche a na-ejikarị eme ihe maka ọgwụ mgbochi ọrịa kansa na ndị ọrịa HLA-A2+ melanoma (Sørensen et al., 2008). Ugboro ugboro ahụ bụ ihe na-eme ka ọ bụrụ ikpe ọkọlọtọ bara uru, na ọ bụkwa ihe na-eme ka nkọwa nkọwa n'okpuru ọnụ.
Kedu ihe mkpuchi usoro pụtara na nkọwapụta ọdọ mmiri, na kedu ka nyocha mkpirisi si dị iche na obere epitopes amachibidoro HLA?
Mkpuchi usoro na-ekwu nke fọdụrụ na protein ezubere iche ọdọ mmiri ahụ na-eweta n'ezie, na nyocha 15-mer na-ebuga obere epitope n'ime peptide ogologo karịa ka 9-mer ma ọ bụ 10-mer.. Usoro mkpuchi na-esote site na mgbakọ na mwepụ: n'akụkụ 15-mers nzọụkwụ 4 foduru, ya mere nke kacha nta 26-35 na 27-35 klas-I epitope na-anọdụ n'ime ogologo peptides ọdọ mmiri, na otu ọdọ mmiri ahụ na-ebu ogologo klas-II-ike 15-mers, nke mere na otu ọdọ mmiri nwere ike ịnya ma CD4 na CD8 readouts (peptides.de, ibe akwụkwọ katalọgụ emechiela ya).
Abụọ eke variants na-abụghị interchangeable reagents. Nwa amaala 26-35 decapeptide EAAGIGILTV na 27-35 AAGIGILTV nonapeptide bụ nke HLA-A * 0201 gosipụtara ma dị iche site na glutamic acid na ọnọdụ peptide otu. (Sørensen et al., 2008). MART-1-kpọmkwem CTL clone ghọtara ma ụdị dị iche iche na mkpụrụ ndụ T2 lysed nke ejiri decapeptide gbadaa na mkpokọta ruo 10 ^-8 mM., ya mere ọdọ mmiri nke na-egosi naanị otu n'ime ha na-anwale ajụjụ dị warara karịa ka akara na-egosi.
Ibe katalọgụ nke na-ekwu naanị "MART-1 peptides" agwabeghị gị mkpuchi mkpuchi ma ọ bụ usoro nke. Ọ gwabeghịkwa gị ma usoro a ọ bụ nwa amaala: ELAGIGILTV reagent dị elu bụ ihe sịntetik [Leu27] analọg, ọ bụghị usoro nke nwa afọ, na katalọgụ nke onye na-ebubata ya na-amata ọdịiche nke nonapeptide na decapeptide nwa afọ., nke nwere obere njikọ njikọ na nkwụsi ike, site na analọg ahụ (peptides.de, ibe akwụkwọ katalọgụ emechiela ya).
Kedu ụlọ ọrụ ọdọ mmiri dabara nke nyocha, na kedu ka azịza dị mma si agbagọ?
Nhazi ọdọ mmiri bụ ọrụ nke nyocha, na a ga-eme atụmatụ nzọụkwụ deconvolution tupu agbaa efere nke mbụ. Deconvolution nke peptide antigens bụ usoro nzọụkwụ abụọ: Nzọụkwụ mbụ na-anwale ihe nlele ahụ na ọdọ mmiri niile ma kpochapụ peptides na-amaghị, na maka peptide ka a ga-amata maka ule agba nke abụọ, ọdọ-mmiri anọ ọ bụla nwere ya ga-agaferịrị nbata (Precopio et al., 2008).
Iwu ọdọ mmiri anọ bụ nke atụmatụ matriks a kpọtụrụ aha. Na nnwale ọtụtụ kụrụ, ọdọ mmiri dị mma anaghị ewepu peptides na-anọghị ya, n'ihi na ndị ọzọ peptides reactive nwere ike ime n'ebe ọzọ. Jiri algọridim ngbanwe akọwapụtara, njikwa na nyocha onye ọ bụla; nyochaa dilution na nnyonye anya tupu ị na-emeso ọdọ mmiri na-adịghị mma dị ka mwepu.
Nọmba nhazi ndị e bipụtara bụ nke otu ikpe, ọ bụghị ọdọ mmiri ọ bụla. Ihe omumu ihe omumu nke HIV ELISpot wuru matrices ọdọ mmiri peptide anọ iji mebie nzaghachi T-cell kpọmkwem nke nje HIV n'ime mmadụ atọ bu ọrịa., na nhazi ya kachasị maka 720 peptides bụ 80 ọdọ mmiri siri ike 36 peptides ọ bụla, na peptide ọ bụla na ọdọ mmiri anọ (Precopio et al., 2008). A na-ahazi ọnụ ọgụgụ ndị ahụ maka ọnụ ọgụgụ peptide ahụ na anaghị agụkọta ọnụ; iwu nwere ike ibufe bụ ọnụọgụ ndị otu, ọ bụghị oke ọdọ mmiri.
Otu akwụkwọ ọmụmụ ebe matrix pooling tụfuru uche, nke bụ akụkụ nkọwapụta kwesịrị ịtụ anya ya. Nzaghachi ugboro ugboro na peptides kpuchiri mpi n'ime ọdọ mmiri emezughị ihe ekwesịrị maka nzaghachi dị mma., na usoro mgbanwe dị iche iche gbochiri ikike nke usoro iji mapụta peptides HIV autologous (Precopio et al., 2008). A tụrụ ike ndị ahụ na usoro antigen dị iche, Ya mere, ha na-egosi ọdịda ọdịda iji chepụta megide karịa ọnụego ịtụ anya na nyocha MART-1.
Kedu ka solubility na reconstitution si egbochi ka enwere ike iji ọdọ mmiri mee ihe?
Solubility na nhazigharị na-ekpebi oke ịta ahụhụ enwere ike iji, na mgbochi nke na-ebu ụzọ ata bụ ihe mgbaze, ọ bụghị peptide. Ntuziaka njikwa ndị na-ebubata ya bụ ịgbari ọdọ mmiri ahụ n'ime obere DMSO dị ọcha ma gbanye ya na mmiri., idobe mkpokọta DMSO ikpeazụ n'okpuru 1% (v/v) iji zere nsị na usoro ndu (peptides.de, ibe akwụkwọ katalọgụ emechiela ya). Ulo ụlọ ahụ na-ekpuchi ole peptide olulu mmiri nwere ike ịnata tupu ihe mgbaze n'onwe ya agbanwee agụ.
Uka nke peptide na per-peptide bụ ọnụọgụ dị iche iche, na nchegharị ahụ na-anọdụ n'etiti ha. Ma TFA na acetate na-agbakwunye uka na-abụghị peptide, na TFA na-enye oke uka kwa otu karịa acetate, yabụ otu usoro a na-enye dị ka nnu TFA na-egosikarị ọdịnaya peptide net dị ala karịa ụdị acetate.. Ọnụ ego nke ọdọ mmiri ahụ kwuru 15 nmol (ihe dị ka 25 µg) kwa peptide na-adabere n'ụdị nnu na ọ bụghị nke a na-atụnyere ozugbo n'ofe ndị na-ebubata ya (peptides.de, ibe akwụkwọ katalọgụ emechiela ya).
Mepụta nkwụsi ike na nchekwa na nhazigharị maka ọdọ mmiri ahụ n'ezie, ihe mgbaze, akpa na ebumnuche nyocha. Ọnọdụ ụlọ ndebanye ọgwụ ICH General abụghị ntuziaka njikwa ma ọ bụ ihe ọmụmụ achọrọ maka ọdọ mmiri peptide nyocha ọ bụla..
Kedu ka esi egosipụta n'otu n'otu ma detuo ya maka ọdọ mmiri peptide?
A na-egosipụta nguzobe ogbe kwa peptide ọ bụla, ọ bụghị kwa ọdọ mmiri, na nkezi ọdọ mmiri bụ otu ihe akaebe na-ezighi ezi. Nkezi ịdị ọcha ọdọ mmiri nwere ike zoo peptides ọ bụla na-efu ma ọ bụ dị ala, n'ihi na a elu-ọcha ọtụtụ na-akwụ ha na pụtara, Ya mere nkọwapụta ahụ kwesịrị ikwupụta ịdị ọcha kacha nta maka onye ọ bụla peptide n'ime ọdọ mmiri karịa nkezi n'ofe ya.
Ndabere nyocha maka nzọrọ per-peptide ahụ bụ usoro akwadoro, na m Q2(R2) nkwado ndabere na mpaghara dị ka ihe dabara adaba maka ebumnuche nke usoro ahụ. Ntuziaka a chọrọ ụkpụrụ nkwado nke na-akọwapụta ebumnuche echere, njirimara arụmọrụ a ga-akwado na njirisi metụtara ha, na tupu ihe ọmụma ziri ezi ebe a na-eji ya, ọ na-akpọkwa nkọwapụta/nhọpụta, izi ezi, nkenke, oke, akuko nso na usoro dabara n'etiti njirimara (I Q2(R2), 2023). Ọnụ ọgụgụ dị ọcha a kọrọ na-enweghị usoro o si bịa abụghị ndekọ na-agbanwe agbanwe.
Identity bụ ọkara nke abụọ nke ndekọ ahụ, na oge njide naanị adịghị eguzobe ya. Nkọwa nkọwa Q6A na-ejide n'aka na njirimara enweghị ike ịdabere n'otu oge njide chromatographic (I Q6A, 2000). Maka ọdọ mmiri peptide, nke ahụ pụtara njirimara uka spectrometry n'akụkụ nsonaazụ ịdị ọcha chromatographic, kwa nza.
Kedu ka esi echekwa ọdọ mmiri, na ihe nyocha nyocha na ndekọ kwesịrị iso ha?
Ihe nchekwa na ihe nyocha chọrọ na-esote ihe ọdọ mmiri na-abanye, na ọkwa nchịkwa na-agbanwe ụkpụrụ ndekọ karịa kemistri. Maka ọtụtụ ebumnuche iji kwado mmemme ahaziri, 21 Akụkụ CFR 11 na-esetịpụ njirisi nke a na-ewere ndekọ eletrọnịkị na mbinye aka eletrọnịkị dị ka ndị a pụrụ ịtụkwasị obi, a pụrụ ịdabere na ya na n'ozuzu ya na ndekọ akwụkwọ na mbinye aka edere (21 Akụkụ CFR 11, mbipụta ugbu a). Otu akụkụ ngalaba na-ekwu na akụkụ ahụ na-emetụta ndekọ n'ụdị eletrọnịkị emepụtara, gbanwee, kwadoro, echekwara, eweghachitere ma ọ bụ bufee ya n'okpuru ihe ndekọ ọ bụla akwadoro na iwu ụlọ ọrụ.
Mpaghara ahụ nwere oke dị mkpa maka mkpebi akwụkwọ ndetu ụlọ nyocha. Akụkụ 11 adịghị emetụta akwụkwọ ndekọ ndị bụ, ma ọ bụ bụrụ, ebufere site na eletrọnịkị (21 Peptide Chain Akụkụ CFR 11, mbipụta ugbu a). Ndekọ akwụkwọ nyocha na ndekọ eletrọnịkị nke ala abụghị otu ihe n'okpuru iwu, nke bụ ajụjụ a ga-edozi tupu ọtụtụ eru eru karịa ka emechara.
Sterility na endotoxin bụ ule dị iche iche na-aza ajụjụ dị iche iche, na CoA kwesịrị ịkọ ha iche iche. USP <85> na-atụba endotoxin nje bacteria na nkeji endotoxin site na ụzọ dabere na LAL, mgbe USP <71> ule maka viable ntule, Ya mere ngafe sterility anaghị egosipụta nsonaazụ endotoxin na endotoxin nwere ike ịdị na-enweghị nje bacteria. (USP, mbipụta ugbu a). Ibe ọdọ mmiri nke ndị na-ebubata ngwaahịa na-ekwu na ngwaahịa a na-enye sterile na endotoxin n'efu, nke bụ nkwupụta na mpaghara data abụọ ahụ dị na-akwado (peptides.de, ibe akwụkwọ katalọgụ emechiela ya).
Iwu mkpebi: ihe ị ga-akọwapụta tupu ị nye iwu ma ọ bụ weghachite
Dee nkọwapụta tupu nhota ahụ, ma jide usoro ahụ ruo mgbe ihe ọ bụla nwere azịza ekwuputara. Usoro ndenye ego n'okpuru na-eso akụkụ ndị dị n'elu n'usoro ha na-amachibido nnwale.
-
Mkpuchi na usoro. Kwupụta geometry nyocha ahụ (15-mers na 11-aa overlap), ogologo protein na ntinye aka nke akọwapụtara mkpuchi, na ma ọdọ mmiri ahụ na-egosi nwa afọ 26-35 na 27-35 variants ma ọ bụ analọgụ gbanwetụrụ. Hexarelin
-
Ihe mejupụtara na deconvolution. Ọ bụrụ na imewe bụ matrix, chọrọ ọnụ ọgụgụ ndị otu kwa peptide ma gosi na a na-eme atụmatụ nnwale onye ọ bụla, na-eji usoro nhazi nhazi nke akọwapụtara na nkwenye onye ọ bụla.
-
Solubility na mgbaze n'uko. Kwenye ihe mgbaze nrụgharị, Onye nrụpụta Peptide omenala olu kacha nta, na njedebe DMSO ikpeazụ nke nyocha ahụ nwere ike ịnabata.
-
ndabere ịdị ọcha. Chọrọ ịdị ọcha kacha nta na-ekwe nkwa maka peptide ọ bụla, ọ bụghị ọnụ ọgụgụ ọdọ mmiri, na usoro na ọnọdụ nkwado ya aha.
-
Njirimara na ọdịnaya. Chọrọ njirimara uka spectrometry kwa nza, na counterion na nnu ụdị, yana ọdịnaya peptide net n'akụkụ ọnụ ọgụgụ ịdị ọcha chromatographic.
-
Ihe mmetọ na ọkwa ndekọ. Chọrọ ịmụ nwa na endotoxin dị ka ubi dị iche iche akọpụtara, ma gosi ma ndekọ nza ahụ dara n'okpuru akụkụ 11 chọrọ ndekọ. Ụlọ ọrụ Peptide S
Ntụle nkọwapụta megide ihe isii ndị a bụ ntinye aka na-esote nzọụkwụ ọzọ: ọ na-efu mkparịta ụka tupu usoro ahụ kama ịnwale nnwale ọzọ mgbe ọ gasịrị.
Ma usoro omenala adịghị arụ ọrụ n'ọnọdụ ụfọdụ?
Ọ na-eme, na ewepụrụ kwesịrị ikwupụta nke ọma karịa ịchụpụ. Otu nkọwa akọwapụtara nwere ike ịbụ azụta ziri ezi mgbe ajụjụ a kpọsaralarị na nzaghachi mmachi HLA., kemgbe nwa afọ 27-35 nonapeptide na 26-35 decapeptide dị ka onye peptides katalọgụ karịa ka ọdọ mmiri (peptides.de, ibe akwụkwọ katalọgụ emechiela ya). Ibu nkọwapụta wee tụgharịa gaa na ajụjụ analọgụ, n'ihi na [Leu27] variant abụghị usoro nwa afọ.
Matrix pooling abụghịkwa na-akpaghị aka ka mma imewe na obere ọnụ ọgụgụ. Ihe ọmụmụ matrix e bipụtara chọrọ karịa 3,000 pipettings kwa matriks, ewezuga nrụzigharị mbụ na mgbaze nke peptides n'otu n'otu maka nyocha agba nke abụọ. (Precopio et al., 2008). Maka obere peptide set, na oru bụ a n'ezie na-eri megide a obi umeala mbelata na sample ojiji.
Mgbaghara kachasị ike bụ na ọdọ mmiri a mara mma abụghị nkwa nke nsonaazụ ndu. Egburu naanị MART-1 kpọmkwem T-cell clone 7 nke 15 a nwalere ahịrị cell melanoma, ebe obere oyiri Bcl-2 akọwapụtara nke ọma gburu ihe niile ma e wezụga otu, wee merie nguzogide site na iji mpempe MART-1 na-akpụgharị mkpụrụ ndụ melanoma (Sørensen et al., 2008). Otu nnyocha ahụ na-akọ na egosipụtaghị epitope MART-1 a na-ejikarị eme ihe n'elu ọtụtụ ahịrị cell melanoma.. Nkọwa ọdọ mmiri ziri ezi na-achịkwa reagent; ọ naghị achịkwa ma ebupụtara ya.
Mmechi
Nke 2035 amụma bụ akara ngosi achọrọ, na ihe bara uru na-eme na mgbama na-achọ bụ imesi nkọwapụta nke a ga-ezute ya. Nkọwa nke amụma amụma ahụ na-ekpuchi ọdọ mmiri ndị akọwapụtagoro nke ọma maka mkpali in vitro na nlekota nke nzaghachi T-cell kpọmkwem antigen., na ya 8.2% CAGR dị elu ka ọ bụrụ index nke siri ike 220 site 2035 bụ usoro ihe atụpụtara karia nha ahịa a tụrụ atụ (IndexBox, 2026-10-11). Ọbịbịa ndị ọzọ n'okpuru nkọwa ngalaba rụrụ arụ na-ebuli ọnụ ahịa nkọwapụta na-ezighi ezi.
Akụkụ isii dị n'elu abụghị ego nlele onwe. Ihe mkpuchi na ihe mejupụtara na-ekpebi ihe ọdọ mmiri nwere ike ịchọpụta, solubility na ihe mgbaze n'uko na-ekpebi ihe ịta ahụhụ nwere ike anabata, na ntọala ịdị ọcha, njirimara, ihe mmetọ na ọkwa ndekọ na-ekpebi ma enwere ike ịgbachitere nza ahụ ma emechaa. Ikpe MART-1 na-egosi ihe kpatara otu ikpeazụ ji dị mkpa: epitope bụ ụdị dị iche iche nwere njikọ dị iche iche na nkwụsi ike, ọ bụghị otu reagent, na nwa afọ 26-35 na 27-35 peptides na-anọdụ n'ime peptides ọdọ mmiri dị ogologo karịa ka a na-egosi ya dị ka obere epitopes (Sørensen et al., 2008).
Tupu ịmaliteghachi, mkpuchi akwụkwọ, njirimara akụrụngwa, ego, solubility, nchekwa na njikwa nyocha. Imezu nkọwapụta na-ebelata ejighị n'aka ihe onwunwe mana enweghị ike iwepụ nnyonye anya metụtara reagent kpamkpam, nbibi ma ọ bụ adabaghị na nyocha nke ndu.
